THC BioMed Receives Buy Rating on Yahoo Finance
THC.CSE THCBF – OTC TFHD.F
Vancouver, Canada – July 11, 2023 -THC BioMed Intl Ltd. (“THC BioMed” or the “Company”), a leading provider of high-quality cannabis products, is pleased to announce that it has received a buy rating on Yahoo Finance.
Yahoo Finance is a prominent financial platform, widely recognized for its comprehensive financial analysis, market data, and investment research, making this rating a significant achievement for THC BioMed.
“We are thrilled to receive a buy rating on Yahoo Finance, a trusted source of financial information,” said John Miller, CEO of THC BioMed. “The buy rating signifies a positive outlook for THC BioMed’s stock, reflecting confidence in the Company’s growth potential and future prospects. This recognition is a testament to our strong performance, strategic initiatives, and commitment to delivering exceptional cannabis products to our customers.”
“We believe that the buy rating is based on a thorough evaluation of THC BioMed’s indicators, including its financials, market position, product portfolio, and growth opportunities. It highlights the Company’s ability to generate value for shareholders and capture a larger share of the expanding cannabis market,” Mr. Miller said.
As THC BioMed continues to drive innovation, enhance operational efficiency, and expand its distribution network, the buy rating on Yahoo Finance serves as an endorsement of the Company’s efforts and provides valuable insights to investors seeking opportunities in the cannabis industry.
Investors and stakeholders are encouraged to visit Yahoo Finance for the full analysis and rating details. THC BioMed’s management team remains committed to creating long-term value for its shareholders while maintaining its position as a trusted leader in the cannabis sector.
About THC BioMed
THC BioMed Intl Ltd. is a Cannabis Act Licensed Producer of medical and recreational cannabis. It is licensed to cultivate and sell dried, extract, edible and topical cannabis. The Company is a pioneer in the cannabis industry, leading in scientific research and the development of products and services, with patient safety as a guiding principle.
For additional information about THC BioMed’s product lines or to stay updated on the Company’s latest developments, visit www.thcbiomed.com.
For more information, media inquiries, or partnership opportunities, please contact:
President and CEO: John Miller
About THC BioMed
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. Forward-looking statements in this release include that (a) the Company has growth opportunities, (b) the Company is able to generate value for shareholders and capture a larger share of the expanding cannabis market, (c) THC BioMed will continue to drive innovation, enhance operational efficiency, and expand its distribution network and (d) THC BioMed’s management will create long-term value for its shareholders and maintain its position as a trusted leader in the cannabis sector.
Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.